Price
$42.30+0.74%Social Signal Score
Analyst Ratings
30 analystsRevenue
$535.04M+57.98%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jon Pratt
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 5,500
- Beta
- 0.63
- Country
- NL
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.58
Financials
Revenue
$535.04M+58.0%Net Income
$103.40M+197.1%EBITDA
$142.13M+40.8%Free Cash Flow
$157.76M+115.3%EPS (diluted)
$0.50+233.3%Shares Outstanding (diluted)
207.83M-13.2%Operating Expenses
$197.20MCash & Debt
$793.50MReturn of Capital
$0.00Revenue by Segment (annual)
$4.18BDividend per Share
$0.35Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.09B | $424.88M | $2.04 |
| 2024 | $1.98B | $83.59M | $0.39 |
| 2023 | $1.97B | $341.30M | $1.67 |
| 2022 | $2.14B | $423.21M | $2.08 |
| 2021 | $2.25B | $512.60M | $2.52 |
| 2020 | $1.87B | $359.19M | $0.33 |
| 2019 | $1.53B | $-41.45M | $-0.19 |
| 2018 | $1.50B | $190.38M | $0.84 |
| 2017 | $1.42B | $40.39M | $0.18 |
| 2016 | $1.34B | $80.40M | $0.36 |
| 2015 | $1.28B | $130.15M | $0.57 |
| 2014 | $1.34B | $116.36M | $0.52 |
| 2013 | $1.30B | $69.07M | $0.31 |
| 2012 | $1.25B | $129.51M | $0.57 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from QGEN's reported EPS growth of 10.3% a year over 13 years.
- EPS in 5 years
- $3.34
- Implied price
- $76.73
- Return from $44.75
- 11.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $38.15 — -14.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| 0.3% | -4.7% | -1.5% | 1.3% | 3.8% | 6.1% |
| 5.3% | 0.1% | 3.4% | 6.3% | 9.0% | 11.4% |
| 10.3% | 4.9% | 8.3% | 11.4% | 14.2% | 16.7% |
| 15.3% | 9.6% | 13.2% | 16.4% | 19.3% | 22.0% |
| 20.3% | 14.4% | 18.1% | 21.5% | 24.5% | 27.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (9)
- Newszacks.com·4d ago·Negative
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.
View source ↗ - Newsbusinesswire.com·8d ago·Negative
…mpletes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria and antibiotic resista…
View source ↗ - Newszacks.com·11d ago·Positive
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·31d ago·Neutral
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue? Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsprnewswire.com·38d ago·Positive
…ing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.
View source ↗ - Newsbusinesswire.com·43d ago·Positive
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, lea…
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Qiagen Q2 Earnings Call Highlights Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.62 per share
Typical surprise +1.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.62 vs $0.60beat
- Wed, May 6$0.54 vs $0.54miss
- Wed, Feb 4$0.62 vs $0.61beat
- Tue, Nov 4$0.64 vs $0.61beat
- Tue, Aug 5$0.60 vs $0.60beat
- Wed, May 7$0.55 vs $0.50beat
Estimates and results for QGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Ro Khannahouse · CA17 · disclosed May 6, 2022 (23d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (22d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (474d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (460d later)Sell$1,001 - $15,000
- Peter Welchhouse · VT00 · disclosed Apr 3, 2020 (10d later)Sell$1,001 - $15,000
- Peter Welchhouse · VT00 · disclosed Mar 10, 2020 (12d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Nov 8, 2019 (31d later)Sell$15,001 - $50,000
- Alan Lowenthalhouse · CA47 · disclosed Nov 8, 2019 (31d later)Sell$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Nov 7, 2019 (30d later)Sell$50,001 - $100,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (8d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (8d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (9d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (8d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (9d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.